Company intelligence / Profile preview

MD Healthcare

Ownership: Private
Development stage: Other

Overview

MD Healthcare is developing a platform leveraging microbiome-derived extracellular vesicles and big data/AI analytics to create both non-invasive diagnostics and novel therapeutics for chronic diseases. As of late 2019/early 2020, their lead programs were in preclinical development with plans to enter clinical trials following completion of GLP toxicity studies. Early diagnostic software was nearing regulatory processes at that time. No published clinical results yet as all assets appear preclinical or at the cusp of IND-enabling work as of last update.

Therapeutic areas: OncologyPulmonologyEndocrinologyPsychiatryDermatologyGastroenterology
Modalities: Small moleculeBiologicMicrobiome-based therapyDiagnostic device/software
Industry: Biotech

Drug pipeline

16 assets

MDH-212

Preclinical

15 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on MD Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MD Healthcare.

Explore the full profile